National Cancer Plan

John Whittingdale Excerpts

Thursday 5th February 2026 Commons Chamber

[Ashley Dalton]

I commend my hon. Friend for the campaigning that he has done in his brother’s name in the area of rare and less survivable cancers, including brain tumours. We are putting patients at the centre of this plan, which says not only that every patient will have a personalised cancer treatment plan, but that patients will be at the heart of deciding those plans. Alongside their clinicians, they will have a role to play in deciding what treatment works for them. I know personally what that means. When I got my diagnosis, the immediate suggestion was that I would have intravenous chemotherapy. I was able to engage with my oncologist and say, “I’m not sure that that works for my lifestyle. I want to be able to live my life.” We were able to work together to find the right treatment that fits in with my lifestyle, and which allows me to come to work and do this job. That is what we want for every single cancer patient in this country. Their treatment should be about not just keeping them alive, but extending and maintaining their quality of life.

[Sir John Whittingdale (Maldon) (Con)]

The league table of NHS trusts shows that the percentage of patients starting treatment for cancer within 62 days in Mid and South Essex is 21%, which puts it bottom of 121 trusts. Can the Minister say what additional help will be given to the Mid and South Essex NHS trust to recruit the additional staff it needs, and to help it to meet the targets that she has just set out?

[Ashley Dalton]

The trust to which the right hon. Gentleman refers is the trust where I had my primary cancer treatment, so I am acutely aware of the challenges. We have set a really clear and simple ambition: to get cancer patients the timely care they need, and to meet all waiting time standards by the end of this Parliament. That means that by March 2029, 80% of patients will get a diagnosis or the all-clear within 28 days, and 85% of patients will start their treatment within 62 days of referral. Some people have asked me why the figure is not 100%. It is not possible to make it 100%, because not everybody’s cancer is simple or easy to identify, and sometimes it takes longer. We want to ensure that the only reason for delays beyond 62 days is the complexity or specifics of someone’s cancer, not the inability of a trust to meet the targets.

We are going to cut waiting times by giving trusts and cancer alliances detailed practical information and granular data on individual cancer types so that we can highlight real-time pathway insights through a federated data platform, and by streamlining the cancer metrics so that we can shine a light on unwarranted variation in care. We are providing information and best practice, thereby taking the best of the NHS to the rest of the NHS. We are linking up professionals and clinicians across the UK, so that they can share their best practice. Trusts can help and support each other to reach the targets.